ArticleWorld journal of gastrointestinal oncology2025
Gallbladder and biliary tract cancer burden trends in Brazil, Russian Federation, India, China, and South Africa in 1990-2021.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Burden of gallbladder and biliary tract cancer (GBTC) in the middle east and North Africa (MENA) from 1990 to 2021: from the global burden of disease (GBD).Annals of medicine and surgery (2012) · 2026Article
- Gallbladder carcinoma in Brazil: Clinicopathological profile and survival outcomes from a high-volume cancer center.World journal of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGallbladder and biliary tract cancer (GBTC) is a highly aggressive malignant tumor with a high fatality rate. The global incidence and mortality of GBTC continue to increase, presenting a significant challenge to public health. Strategies for preventing and controlling GBTC in Brazil, Russian Federation, India, China and South Africa (BRICS) countries offer valuable lessons for other developing nations.
aimTo investigate GBTC burden trends in BRICS countries and perform an age-period-cohort (APC) analysis of Global Burden of Disease (GBD) from 1990-2021.
methodsData on the incidences and crude incidence rates, the number of deaths and crude mortality rates, and the age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) of GBTC were obtained for BRICS countries from the GBD study 2021. Joinpoint regression analysis was employed to examine the trends in disease burden from 1990 to 2021. The APC model was utilized to assess the age, period, and birth cohort effects on the changes in GBTC disease burden worldwide and in the BRICS countries during the same time frame. Bayesian APC analysis was used to estimate the future burden.
resultsThe increases in incidence and deaths were 101.09% and 74.26%, respectively, compared with 1990. The ASMRs in Brazil, Russia, and China decreased, while those in India and South Africa increased. Among the BRICS countries, in most age groups in Brazil, Russia, India, and South Africa, the crude incidence and mortality rates in women were higher than those in men, whereas in China, the situation was the opposite. Joinpoint regression analysis revealed that from 1990 to 2021, the overall ASIR of gallbladder and bile duct cancer exhibited a declining trend. Although the incidence rate in China showed an increasing trend, the mortality rate exhibited a declining trend, which became more pronounced over time.
conclusionIn BRICS countries, the number of incident cases and deaths from GBTC increased between 1990 and 2021, primarily due to rapid population growth. Nevertheless, the ASIR and ASMR declined during the same period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.